Ildong wins telmisartan patent

Ildong Pharmaceutical said Thursday that it has obtained a Korean patent to produce the intermediate of telmisartan (2-n-prophyl-4-methyl-6-(1-methylbenzimidazole-2-yl)-1H-benzimidazole) on a mass scale.

Telmisartan is an angiotensin II receptor antagonist (angiotensin receptor blocker, ARB) used in the management of hypertension. It is marketed under the trade name Micardis (by Boehringer I...